Table 2.
Patient characteristics
| Number of patients | |
|---|---|
| Characteristics | n = 277, n (%) |
| Age, median (range) | median 65 (29–88) |
| Gender | |
| Male | 93 (34) |
| Female | 184 (66) |
| Primary disease | |
| Breast cancer | 159 (57) |
| Prostate cancer | 26 (9) |
| Pancreatic cancer | 13 (5) |
| Lung cancer | 12 (4) |
| RCC | 12 (4) |
| Gastric cancer | 11 (4) |
| Carcinoma of unknown primary | 8 (3) |
| Colorectal cancer | 8 (3) |
| Esophageal cancer | 5 (2) |
| Urothelial cancer | 4 (1) |
| Melanoma | 2 (1) |
| Hepatocellular carcinoma | 2 (1) |
| Others | 15 (5) |
| Stage at diagnosis | |
| I | 21 (8) |
| II | 58 (22) |
| III | 46 (17) |
| IV | 94 (35) |
| Unknown | 46 (17) |
| Perioperative chemotherapy | |
| Yes | 80 (29) |
| No | 195 (70) |
| Unknown | 2 (1) |
| Metastatic site | |
| Lung | 120 (43) |
| Liver | 107 (39) |
| Lymph node | 147 (53) |
| Bone | 277 (100) |
| Brain | 28 (10) |
| Pleura | 23 (8) |
| Peritoneum | 20 (7) |
| Adrenal gland | 17 (6) |
| Others | 19 (7) |
| Prior zoledronic acid treatment | |
| Yes | 56 (20) |
| No | 167 (60) |
| Unknown | 54 (19) |
| Number of doses of denosumab | median 10 (1–79) |
| More than 45 doses of denosumab | 16 (5) |